Completed NA INTERVENTIONAL 1-arm NCT04260113

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study

Sponsor: Peking University People's Hospital

Updated 5 times since 2020 Last updated: Jan 2, 2021 Started: Oct 1, 2019 Primary completion: Jan 1, 2020 Completion: Apr 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04260113, this NA trial focuses on Efficacy and Toxicity, Drug and remains completed. Sponsored by Peking University People's Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Feb 2021 — Jul 2024 [monthly]

Completed NA

Status: Active Not Recruiting → Completed
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting NA
Mar 2020 — Jan 2021 [monthly]

Active Not Recruiting NA

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University People's Hospital

Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China